Mucograft xenogeneic collagen matrix,
does it really help with Root coverage noninferior to autologous connective-tissue grafting in multiple adjacent gingival recessions?
research showsThe grade is D. In the 14-center trial of 187 participants and 485 recessions, six-month root coverage was 1.7±1.1 mm with Mucograft versus 2.1±1.0 mm with autologous connective tissue. The difference favoring autograft was 0.44 mm (95% CI 0.25 to 0.63), while the prespecified noninferiority margin was 0.25 mm. Because the upper confidence limit of 0.63 mm crossed the margin, Mucograft failed noninferiority, giving D with 28 points.
ads claimThe matrix must not be described as equivalent to autograft. Primary root-coverage noninferiority failed and connective tissue grafting was better. Separate secondary advantages can be stated accurately: surgery was 15.7 minutes shorter and recovery was 1.8 days shorter because palatal harvesting was avoided.
Useful facts when choosing a product
- Mucograft is a Geistlich xenogeneic collagen matrix placed under a coronally advanced flap.
- The comparator added autologous connective tissue harvested from the palate to the same flap procedure.
- Geistlich contributed unrestricted funding and donated trial materials; investigators reported independent conduct of all study phases.
What the research actually shows
At 14 centers, 187 participants with 485 recessions were randomized to autologous connective tissue (95) or Mucograft (92); all received treatment and completed six-month follow-up. A central registrar used computer-generated permuted blocks, allocation was concealed from surgeons in opaque envelopes until completion of the shared surgical portion, and questionnaire staff and clinical examiners were masked. The primary multilevel model included center, participant, and tooth levels with baseline adjustment. Root coverage was 1.7±1.1 versus 2.1±1.0 mm, difference 0.44 mm (0.25 to 0.63), failing noninferiority. ERGOPerio sponsored the trial, while Geistlich Pharma AG provided part of the funding through an unrestricted grant and supplied the regenerative materials as ‘a gift.’ These were trial interventions, not assessment tools. The article states that investigators independently designed, conducted, analyzed, interpreted, and reported the study.
Why this is classified as D (28)
Primary root-coverage noninferiority failed in one small active-controlled noninferiority trial with partial manufacturer funding and material donation, giving D with 28 points; secondary recovery benefits remain separate.
Counterpoint. D does not mean Mucograft has no advantage. The equivalence claim failed, while reduced surgical burden may still matter in shared decision-making.
Rejudgment record. Cross-check applied — Centers the failed primary root-coverage noninferiority result, difference 0.44 mm (0.25 to 0.63) against a 0.25-mm margin, while separating the secondary 15.7-minute operating-time and 1.8-day recovery benefits
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Root coverage noninferior to autologous connective tissue | D | The upper CI of 0.63 mm exceeded the 0.25-mm margin, so noninferiority failed. |
| Shorter operating time | C | Surgery was 15.7 minutes shorter (95% CI 11.9 to 19.6). |
| Shorter recovery | C | Return to baseline OHIP-14 was 4.2 versus 6.0 days, 1.8 days shorter. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Assessor-masked 14-center randomized trial of root-coverage noninferiority and patient-reported superiority | 6 | Sponsored by ERGOPerio; Geistlich Pharma AG provided partial unrestricted funding and donated regenerative trial materials | Noninferiority in six-month root coverage measured by gingival-margin position change | 1.7±1.1 versus 2.1±1.0 mm; difference favoring autograft 0.44 mm (95% CI 0.25 to 0.63), exceeding the 0.25-mm margin; complete root coverage OR 4.0 (1.8 to 8.8) for autograft | Failed primary noninferiority; one small active-controlled noninferiority trial with mixed funding |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Mucograft xenogeneic collagen matrix x root coverage of multiple gingival recessions — Evidence Grade D·28. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/general/mucograft-multiple-gingival-recession-root-coverage-noninferiority/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.